The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria
Abstract
Guillain-Barré syndrome is an acute polyradiculoneuropathy with a variable clinical presentation. Accurate diagnostic criteria are essential for patient care and research, including clinical trials and vaccine safety studies. Several diagnostic criteria for Guillain-Barré syndrome have been proposed, including the recent set by the Brighton Collaboration. In the present study we describe in detail the key diagnostic features required to meet these Brighton criteria in a study population of 494 adult patients with Guillain-Barré syndrome, previously included in therapeutic and observational studies. The patients had a median age of 53 years (interquartile range 36-66 years) and males slightly predominated (56%). All patients developed bilateral limb weakness which generally involved both upper and lower extremities. The weakness remained restricted to the legs in 6% and to the arms in 1% of the patients. Decreased reflexes in paretic arms or legs were found initially in 91% of patients and in all patients during follow-up. Ten (2%) patients however showed persistence of normal reflexes in paretic arms. Disease nadir was reached within 2 weeks in 80%, within 4 weeks in 97% and within 6 weeks in all patients. A monophasic disease course occurred in 95% of patients, of whom 10% had a treatment-related fluctuation. A clinical deterioration after 8 weeks of onset of weakness occurred in 23 (5%) patients. Cerebrospinal fluid was examined in 474 (96%) patients. A mild pleocytosis (5 to 50 cells/μl) was found in 15%, and none had more than 50 cells/μl. An increased cerebrospinal fluid protein concentration was found only in 64% of patients, highly dependent on the timing of the lumbar puncture after onset of weakness (49% at the first day to 88% after 2 weeks). Nerve electrophysiology was compatible with the presence of a neuropathy in 99% of patients, but only 59% fulfilled the current criteria for a distinct subtype of Guillain-Barré syndrome. Patients with a complete data set (335) were classified according to the Brighton criteria, ranging from a high to a low level of diagnostic certainty, as level 1 in 61%, level 2 in 33%, level 3 in none, and level 4 in 6% of patients. Patients categorized in these levels did not differ with respect to proportion of patients with preceding events, initial clinical manifestations or outcome. The observed variability in the key diagnostic features of Guillain-Barré syndrome in the current cohort study, can be used to improve the sensitivity of the diagnostic criteria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessment of current diagnostic criteria for Guillain-Barr� syndrome
Asbury, A. K., & Cornblath, D. R. (1990) · Annals of Neurology · doi:10.1002/ana.410270707 · Cited by 1,905
Hughes, R. A., & Cornblath, D. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67665-9 · Cited by 1,676
Yuki, N., & Hartung, H.-P. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1114525 · Cited by 1,260
van der Meché, F. G. A., Schmitz, P. I. M., & the Dutch Guillain–Barré Study Group* (1992) · New England Journal of Medicine · doi:10.1056/nejm199204233261705 · Cited by 1,143
CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHY
Hughes, R. A. C., Newsom-Davis, J. M., Perkin, G. D., & Pierce, J. M. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92644-2 · Cited by 1,123
Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome
Hadden, R. D. M., Cornblath, D. R., Hughes, R. A. C., Zielasek, J., Hartung, H. ‐., Toyka, K. V., Swan, A. V., & The Plasma Exchange/Sandoglobulin Guillain‐Barré Syndrome Trial Group (1998) · Annals of Neurology · doi:10.1002/ana.410440512 · Cited by 942
Kleyweg, R. P., Van Der Meché, F. G. A., & Schmitz, P. I. M. (1991) · Muscle & Nerve · doi:10.1002/mus.880141111 · Cited by 926
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
van Doorn, P. A., Ruts, L., & Jacobs, B. C. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70215-1 · Cited by 828
Self-citationSCHONBERGER, L. B., BREGMAN, D. J., SULLIVAN-BOLYAI, J. Z., KEENLYSIDE, R. A., ZIEGLER, D. W., RETAILLIAU, H. F., EDDINS, D. L., & BRYAN, J. A. (1979) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112795 · Cited by 785
Sejvar, J. J., Kohl, K. S., Gidudu, J., Amato, A., Bakshi, N., Baxter, R., Burwen, D. R., Cornblath, D. R., Cleerbout, J., Edwards, K. M., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.06.003 · Cited by 652
Odaka, M., Yuki, N., Yamada, M., Koga, M., Takemi, T., Hirata, K., & Kuwabara, S. (2003) · Brain · doi:10.1093/brain/awg233 · Cited by 440
Griffin, J. W., Li, C. Y., Ho, T. W., Xue, P., Macko, C., Gao, C. Y., Yang, C., Tian, M., Mishu, B., Cornblath, D. R., et al. (1995) · Brain · doi:10.1093/brain/118.3.577 · Cited by 366
Uncini, A., & Kuwabara, S. (2012) · Clinical Neurophysiology · doi:10.1016/j.clinph.2012.01.025 · Cited by 263
Conduction block in acute motor axonal neuropathy
Kokubun, N., Nishibayashi, M., Uncini, A., Odaka, M., Hirata, K., & Yuki, N. (2010) · Brain · doi:10.1093/brain/awq260 · Cited by 194
The immunobiology of Guillain‐Barré syndromes
Willison, H. J. (2005) · Journal of the Peripheral Nervous System · doi:10.1111/j.1085-9489.2005.0010202.x · Cited by 189
Kleyweg, R. P., & van der Meché, F. G. A. (1991) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.11.957 · Cited by 155
Distinguishing acute-onset CIDP from Guillain–Barré syndrome with treatment related fluctuations
Ruts, L., van Koningsveld, R., & van Doorn, P. A. (2005) · Neurology · doi:10.1212/01.wnl.0000167549.09664.b8 · Cited by 151
Guillain–Barré syndrome in children: Clinical course, electrodiagnosis, and prognosis
Bradshaw, D. Y., & Jones, H. R. (1992) · Muscle & Nerve · doi:10.1002/mus.880150415 · Cited by 148
Guillain–Barré syndrome associated with normal or exaggerated tendon reflexes
Yuki, N., Kokubun, N., Kuwabara, S., Sekiguchi, Y., Ito, M., Odaka, M., Hirata, K., Notturno, F., & Uncini, A. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6330-4 · Cited by 117
The Dutch Guillain‐Barré Study Group (1994) · Annals of Neurology · doi:10.1002/ana.410350618 · Cited by 115
Subacute Idiopathic Demyelinating Polyradiculoneuropathy
Hughes, R. A., Sanders, E., Hall, S. M., Atkinson, P. F., Colchester, A. C. F., & Payan, P. C. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530300044009 · Cited by 112
Cerebrospinal fluid biomarkers in Guillain-Barré syndrome – Where do we stand?
Brettschneider, J., Petzold, A., Süßmuth, S. D., & Tumani, H. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0097-x · Cited by 82
Passage of intravenous immunoglobulin and interaction with the CNS.
Wurster, U., & Haas, J. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.suppl.21 · Cited by 51
Cerebrospinal Fluid Parameters in Healthy Volunteers During Serial Lumbar Punctures
Menachem, E. B., Persson, L., Schechter, P. J., Haegele, K. D., Huebert, N. D., & Hardenberg, J. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09166.x · Cited by 34
Guillain‐Barré syndrome: background incidence rates in The Netherlands
van der Maas, N., Kramer, M. A., Jacobs, B. C., van Soest, E. M., Dieleman, J. P., Kemmeren, J. M., de Melker, H. E., & Sturkenboom, M. (2011) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2011.00356.x · Cited by 21
Self-citation
Cited by
Cao-Lormeau, V.-M., Blake, A., Mons, S., Lastère, S., Roche, C., Vanhomwegen, J., Dub, T., Baudouin, L., Teissier, A., Larre, P., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00562-6 · Cited by 2,205
Willison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00339-1 · Cited by 1,609
Self-citationGuillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis
van den Berg, B., Walgaard, C., Drenthen, J., Fokke, C., Jacobs, B. C., & van Doorn, P. A. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.121 · Cited by 1,101
Self-citationDiagnosis and management of Guillain–Barré syndrome in ten steps
Leonhard, S. E., Mandarakas, M. R., Gondim, F. A. A., Bateman, K., Ferreira, M. L. B., Cornblath, D. R., van Doorn, P. A., Dourado, M. E., Hughes, R. A. C., Islam, B., et al. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0250-9 · Cited by 910
Self-citationGuillain–Barré and Miller Fisher syndromes—new diagnostic classification
the GBS Classification Group, Wakerley, B. R., Uncini, A., & Yuki, N. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.138 · Cited by 544
Metadata
- Authors
- Fokke, C., van den Berg, B., Drenthen, J., Walgaard, C., van Doorn, P. A., & Jacobs, B. C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-10-26
- Volume
- 137
- Issue
- 1
- Pages
- 33-43
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2130371608
- Cited by
- 792
- References
- 25
- FWCI
- 15.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.